CATX•benzinga•
Perspective, Therapeutics Has Dosed The First Patient In A New Cohort Of A Phase 1/2a Trial Evaluating The Safety Of [212Pb]VMT01, A Targeted Alpha-particle Therapy, In Patients With Histologically Confirmed Melanoma And Positive Melanocortin 1 Receptor I
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 17, 2025 by benzinga